Pfizer Inc.: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-05-22
Other years: 2026 vs 2025 · 2025 vs 2024
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Pfizer's 2024 risk disclosures reflect a strategic pivot toward cybersecurity threats, introducing this as a standalone risk factor while removing the standalone ENVIRONMENTAL MATTERS disclosure. The company substantially revised 22 of its 26 risk factors, with notably expanded language in INFORMATION TECHNOLOGY AND SECURITY, GOVERNMENT REGULATION AND PRICE CONSTRAINTS, and DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS, indicating heightened concern around digital vulnerabilities, regulatory pressures, and product lifecycle management.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
1
Removed
22
Modified
3
Unchanged
🟢 New in Current Filing CYBERSECURITY 🔒
🔴 No Match in Current Filing ENVIRONMENTAL MATTERS 🔒
🟡 Modified CHANGES IN LAWS AND ACCOUNTING STANDARDS 🔒
🟡 Modified GLOBAL OPERATIONS 🔒
🟡 Modified INFORMATION TECHNOLOGY AND SECURITY 🔒
🟡 Modified LEGAL MATTERS 🔒
🟡 Modified COMPETITIVE PRODUCTS 🔒
🟡 Modified COUNTERFEIT PRODUCTS 🔒
🟡 Modified BUSINESS DEVELOPMENT ACTIVITIES AND STRATEGIC GOALS 🔒
🟡 Modified GOVERNMENT REGULATION AND PRICE CONSTRAINTS 🔒
🟡 Modified CLIMATE CHANGE AND SUSTAINABILITY 🔒
🟡 Modified DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS 🔒
🟡 Modified THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS 🔒
🟡 Modified POST-AUTHORIZATION/APPROVAL DATA 🔒
🟡 Modified U.S. HEALTHCARE REGULATION 🔒
🟡 Modified ENVIRONMENTAL MATTERS 🔒
🟡 Modified RESEARCH AND DEVELOPMENT 🔒
🟡 Modified COST AND EXPENSE CONTROL AND NONORDINARY EVENTS 🔒
🟡 Modified CONCENTRATION 🔒
🟡 Modified PRICING AND REIMBURSEMENT 🔒
🟡 Modified PRODUCT MANUFACTURING, SALES AND MARKETING RISKS 🔒
🟡 Modified MANAGED CARE TRENDS 🔒
🟡 Modified MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS 🔒
🟡 Modified RAW MATERIALS 🔒
24 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →